ALZN vs ANNX

Alzamend Neuro, Inc. vs Annexon, Inc. — Valuation Comparison 2026

ALZN

Biotechnology
Alzamend Neuro, Inc.
Quality
4.1
out of 10
Value Trap
12
SAFE
Price
$1.15
Last close
Models
7/13
Active
VS

ANNX

Biotechnology
Annexon, Inc.
Quality
4.2
out of 10
Value Trap
36
LOW
Price
$5.37
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ALZN Fair ValueALZN Upside ANNX Fair ValueANNX Upside
Bayesian DCF Intrinsic $0.70 -39.3% $1.97 -63.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.05 -95.4% $0.09 -98.4%
Dynamic NAV Asset-Based $2.27 +97.0% $2.02 -62.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ALZN vs ANNX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ALZN vs ANNX — Which Stock Is More Undervalued?

ANNX scores higher with a 4.2/10 quality rating vs ALZN's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Alzamend Neuro, Inc. (ALZN) and Annexon, Inc. (ANNX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ALZN currently trades at $1.15 with a QOC of 4.1/10, while ANNX trades at $5.37 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).